Health care undoubtedly appears to be the driver of future economic growth. The industry, a big frontrunner in the stock market over the past year, has advantaged from the changing demographics of the U.S. population.

More traditional drug-making corporations like Merck should also take advantage from the demographic move. Merck is predictable to post yearly sales of $42 billion when it states on Friday, a minor cut from 2013.

Following are the few healthcare stocks (along with their complete data), that ended Friday’s trading session, in a red-zone:

First of All, AbbVie, (NYSE:ABBV), declined -4.39% to settle at $60.35, during the last trading session, following the company publicized top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. The primary endpoint of the GIFT-I study was achieved, representing a 95 percent (n=106/112) sustained virologic response rate at 12 weeks post treatment (SVR12) in the sub-group of formerly untreated, non-cirrhotic adult GT1b Japanese patients who were eligible for therapy with interferon (IFN) and had a high viral load.

AbbVie Inc (ABBV), is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Arena Pharmaceuticals, (NASDAQ:ARNA), lowered -4.43% to $4.31, during the last trading session, soon after a biopharmaceutical organization, declared that it has sold 21,000,000 shares of ordinary stock to Jefferies LLC and Piper Jaffray & Co. as underwriters for its formerly declared public offering. The underwriters offered the shares to purchasers in transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

Arena Pharmaceuticals, Inc (ARNA), a biopharmaceutical organization, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The organization offers BELVIQ, a drug used to treat chronic weight administration in adults.

Mylan, (NASDAQ:MYL), dipped -3.16% to $53.15, during the last trading session, after a pharmaceutical organization, declared that at a Special Meeting of Shareholders held Jan. 29, 2015, Mylan’s shareholders devastatingly accepted the contract implementing Mylan’s pending attainment of Abbott’s (ABT) non-U.S. developed markets specialty and branded generics business and reorganization in the Netherlands in an all-stock transaction. The contract implementing the transaction received the approval of about 98% of the votes cast and the advisory vote on the proposal regarding certain compensation matters related to the transaction received the approval of about 82% of the votes cast.

Mylan Inc (MYL), a pharmaceutical organization, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty.

Eli Lilly and Co (NYSE:LLY), dropped -0.15% to $72.00, during the last trading session, following the company declared financial results for the fourth quarter and full year of 2014. Certain financial information for 2014 and 2013 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and comprise all revenue and expenses recognized during the period. Non-GAAP measures exclude the items described in the reconciliation tables later in the release.

Eli Lilly and Co (LLY), discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products.